Pfizer's BRAFTOVI + MEKTOVI Shows Sustained Long-Term Survival In Patients With Advanced Lung Cancer
Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib ...
The US Food and Drug Administration granted 510(k) marketing clearances for various tests to aid the diagnosis and treatment of infectious diseases, among other products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback